Eli Lilly is expected to announce Friday that it will spend $5.3B to boost manufacturing capacity for its anti-obesity drug Zepbound and cousin diabetes drug Mounjaro, according to The Wall Street Journal’s Peter Loftus. Lilly will significantly expand a production site that is under construction on 600 acres in Lebanon, Indiana and together with funding that it previously committed, Lilly will spend $9B total on the new site, which The Journal calls “the largest manufacturing investment in its history.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly pays $60M upfront for radiopharmaceutical pact with Aktis
- Early notable gainers among liquid option names on May 21st
- Eli Lilly’s mirikizumab shows efficacy in Crohn’s disease
- Hims & Hers soars after announcing $199 weight loss shots
- Jefferies healthcare analysts hold an analyst/industry conference call